Personnel

Pharma company names senior vice president

Published in Gene Therapy Weekly, January 6th, 2005

POZEN Inc. (NASDAQ: POZN) announced the appointment of William Stagner, RPh, PhD, an executive with 25 years of pharmaceutical development experience, as senior vice president, program management and development planning.

Stagner will be responsible for management of the company's project development teams and programs.

"Stagner is an outstanding pharmaceutical executive who brings to POZEN years of experience in the management of pharmaceutics, preclinical, and clinical development programs, as well as experience as a general manager," said Dr. John R. Plachetka, POZEN's chairman, president, and chief executive officer.

Stagner...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-01-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry